HPV16 E6 Seropositivity and ctHPVDNA for Early Detection of Oropharyngeal Cancer
Description: Human papillomavirus (HPV) infection causes 6 cancers – cervical, anal, vaginal, vulvar, penile and oropharyngeal cancer. While we have very effective HPV vaccines, most of the US population is not vaccinated and is still at high risk for developing HPV-associated cancers. In the US, we have observed a rapid increase in HPV-driven oropharyngeal cancer (HPV-OPC), a type of throat cancer caused by oral HPV infection. Over the past few decades, the incidence of HPV-OPC has increased by over 200%. Kentucky has one of the highest rates in the US. Unlike cervical cancer, 85% of HPV-OPC cases occur among men and there is no method of early detection. While “pap testing” is highly effectively for the early detection of cervical cancer, this method does not work for HPV-OPC. Research gap: We need to develop new methods for early detection of HPV-OPC. We recently identified a promising early marker of HPV-OPC. The HPV16 E6 antibody marker is present in the blood in 90% of HPV-OPC patients at the time of diagnosis. When we tested blood samples stored years before men developed HPV-OPC, we found that the HPV16 E6 antibody marker could appear more than 10 years prior to diagnosis. Yet, not all individuals with HPV16 E6 antibodies develop HPV-OPC. Thus, for individuals with HPV16 E6 antibodies, we also need an early detection biomarker to tell us if they have a tumor. Circulating tumor HPV DNA (ctHPVDNA) is a promising marker for detecting HPV-OPC cancer cells. ctHPVDNA is present in nearly all HPV-OPC patients at diagnosis, and can now be non-invasively detected in urine using our unique technology. The objective of this study is to understand whether HPV16 E6 antibodies and ctHPVDNA can be used for the early detection of HPV-OPC. 3,000 men will be recruited from primary care clinics in urban Lexington and rural Appalachian Kentucky. Men will be screened for HPV16 E6 antibodies using a simple finger prick and blood spot card. All men with HPV16 E6 antibodies and some without, will be invited to have a one-time head and neck cancer screening exam to determine whether they have HPV-OPC. Men not diagnosed with HPV-OPC during the exam will be tested yearly for ctHPVDNA using self-collected urine specimens. Any man with detectable ctHPVDNA in their urine will be invited for a repeat exam to find out if they have developed HPV-OPC. We hypothesize that men with HPV16 E6 antibodies and ctHPVDNA will be more likely to have undiagnosed HPV-OPC than men without and that the accuracy of these markers for diagnosing HPV-OPC will be comparable to other clinically used cancer screening tests. This research is significant in that it may help us create new methods for early detection of HPV-OPC. This research is particularly important given that Kentucky has a high and increasing rate of OPC. This proposal is innovative because we can test for these markers using samples that patients can collect at home and mail to the lab. This would allow us to reach more people, especially those who do not live close to a medical facility, such as rural Appalachia.
Funder: American Cancer Society
Amount: $1,200,000
Funding type: award
Start date: 2024-01-01
End date: 2028-12-31
Investigator: Krystle Kuhs (lead)
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Funded outputs count: 0
Funder award ID: SPA-RFA-Team-24-1076353-01-PASD
OpenAlex ID: G7089766022
